Full Press Release Details
BOSTON--(BUSINESS WIRE)--IHI, in partnership with Bristol Myers Squibb (BMS), is launching a new Cancer Collective Action Collaborative.
BMY Positive Sentiment
IHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials
Key Takeaway: IHI and Bristol Myers Squibb have initiated a new Cancer Collective Action Collaborative. This partnership aims to enhance access to cancer clinical trials, improving opportunities for patients to participate in innovative therapies. The initiative seeks to address barriers that limit patient enrollment in these critical studies.
Market Sentiment Analysis
POSITIVE FACTORS
- New collaborative aims to expand access to cancer trials.
- Partnership with Bristol Myers Squibb enhances credibility.
- Focus on improving patient access to innovative therapies.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+16%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
CC-95266
Phase 1 · Multiple Myeloma
Frequently Asked Questions
What is the purpose of the new collaborative?
The collaborative aims to expand access to cancer clinical trials.
Who are the partners in this initiative?
The initiative is a partnership between IHI and Bristol Myers Squibb.
How will this collaborative benefit patients?
It seeks to improve patient access to innovative cancer therapies.
What barriers does the collaborative address?
It addresses barriers that limit patient enrollment in clinical trials.